Evidence of acrolein in synovial fluid of dogs with osteoarthritis as a potential inflammatory biomarker.
Acrolein
Dogs
FDP-lysine, acrolein-lysine adduct, MMP2
Osteoarthritis
Synovial fluid
Journal
BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565
Informations de publication
Date de publication:
20 Oct 2021
20 Oct 2021
Historique:
received:
06
04
2021
accepted:
04
10
2021
entrez:
21
10
2021
pubmed:
22
10
2021
medline:
27
10
2021
Statut:
epublish
Résumé
Acrolein is a known pro-inflammatory toxic aldehyde, propagating cellular damage and tissue inflammation in humans and animal models of various diseases. Osteoarthritis (OA) has a significant inflammatory component; however, presence of acrolein in synovial fluid of joints with OA has not been previously reported. The first aim of this study was to evaluate evidence of acrolein in the synovial fluid of dogs with OA as well as in Control joints. The second aim was to determine if evidence of acrolein can be detected in synovial fluid samples that have been in a frozen state for long periods of time. In this pilot clinical study, synovial fluid samples were prospectively collected (i.e., New samples) from a single joint of both clinically healthy (New Control, n = 5) and dogs with OA (New OA, n = 16) and frozen until the time of analysis. Additionally, frozen synovial fluid samples from a biobank (i.e., Old samples) were used to evaluate ability to detect evidence of acrolein in long-term stored samples (median of 4.89 years) in Old Control (n = 5) and Old OA (n = 5) samples. Measurements of acrolein in all synovial fluid samples was based on detection of its major protein adduct, N ε - (3-formyl-3, 4-dehydropiperidino)lysine (FDP-lysine), using the western blot method. Synovial fluid matrix metalloproteinase 2 (MMP2) was measured in all samples using the western blot method as a positive control of OA inflammation. Acrolein-lysine adduct was detected in both Control (n = 10) and OA (n = 21) groups in both Old and New samples. Acrolein-lysine adduct and MMP2 were detectable at a lower level in the Old compared to New synovial fluid samples; however, the differences were not statistically significant (p > 0.1). The measured MMP2 levels were significantly higher in the OA compared to Control group samples (p = 0.033), but not for acrolein-lysine adduct (p = 0.30). This study confirmed evidence of acrolein in canine synovial fluid of both OA and Control groups. Freezing of synovial fluid for up to 5 years does not appear to significantly affect the ability to detect acrolein-lysine adduct and MMP2 in these samples.
Sections du résumé
BACKGROUND
BACKGROUND
Acrolein is a known pro-inflammatory toxic aldehyde, propagating cellular damage and tissue inflammation in humans and animal models of various diseases. Osteoarthritis (OA) has a significant inflammatory component; however, presence of acrolein in synovial fluid of joints with OA has not been previously reported. The first aim of this study was to evaluate evidence of acrolein in the synovial fluid of dogs with OA as well as in Control joints. The second aim was to determine if evidence of acrolein can be detected in synovial fluid samples that have been in a frozen state for long periods of time.
METHODS
METHODS
In this pilot clinical study, synovial fluid samples were prospectively collected (i.e., New samples) from a single joint of both clinically healthy (New Control, n = 5) and dogs with OA (New OA, n = 16) and frozen until the time of analysis. Additionally, frozen synovial fluid samples from a biobank (i.e., Old samples) were used to evaluate ability to detect evidence of acrolein in long-term stored samples (median of 4.89 years) in Old Control (n = 5) and Old OA (n = 5) samples. Measurements of acrolein in all synovial fluid samples was based on detection of its major protein adduct, N ε - (3-formyl-3, 4-dehydropiperidino)lysine (FDP-lysine), using the western blot method. Synovial fluid matrix metalloproteinase 2 (MMP2) was measured in all samples using the western blot method as a positive control of OA inflammation.
RESULTS
RESULTS
Acrolein-lysine adduct was detected in both Control (n = 10) and OA (n = 21) groups in both Old and New samples. Acrolein-lysine adduct and MMP2 were detectable at a lower level in the Old compared to New synovial fluid samples; however, the differences were not statistically significant (p > 0.1). The measured MMP2 levels were significantly higher in the OA compared to Control group samples (p = 0.033), but not for acrolein-lysine adduct (p = 0.30).
CONCLUSIONS
CONCLUSIONS
This study confirmed evidence of acrolein in canine synovial fluid of both OA and Control groups. Freezing of synovial fluid for up to 5 years does not appear to significantly affect the ability to detect acrolein-lysine adduct and MMP2 in these samples.
Identifiants
pubmed: 34670524
doi: 10.1186/s12891-021-04762-z
pii: 10.1186/s12891-021-04762-z
pmc: PMC8529717
doi:
Substances chimiques
Biomarkers
0
Acrolein
7864XYD3JJ
Matrix Metalloproteinase 2
EC 3.4.24.24
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
894Informations de copyright
© 2021. The Author(s).
Références
Mol Cell Neurosci. 2018 Apr;88:70-82
pubmed: 29414104
Sci Transl Med. 2014 Aug 27;6(251):251ra118
pubmed: 25163478
Respir Physiol Neurobiol. 2010 Dec 31;174(3):299-306
pubmed: 20804863
Sci Rep. 2018 Apr 4;8(1):5641
pubmed: 29618832
Mod Rheumatol. 2021 Mar;31(2):357-364
pubmed: 32463710
Mol Cell Neurosci. 2019 Jul;98:140-154
pubmed: 31201929
J Pharmacol Toxicol Methods. 2010 Mar-Apr;61(2):171-7
pubmed: 20006725
Free Radic Biol Med. 1991;11(1):81-128
pubmed: 1937131
Free Radic Res. 2016;50(3):304-13
pubmed: 26764956
J Biol Chem. 2003 Dec 5;278(49):48658-65
pubmed: 14504272
J Am Anim Hosp Assoc. 2010 Jul-Aug;46(4):285-96
pubmed: 20610704
Vet Radiol Ultrasound. 2004 Mar-Apr;45(2):143-8
pubmed: 15072147
PLoS One. 2013;8(2):e56246
pubmed: 23418544
Rheumatology (Sunnyvale). 2015;Suppl 6:006
pubmed: 26594594
J Am Vet Med Assoc. 2013 Jun 1;242(11):1549-55
pubmed: 23683021
Osteoarthritis Cartilage. 2016 Jan;24(1):9-20
pubmed: 26707988
Mol Nutr Food Res. 2008 Jan;52(1):7-25
pubmed: 18203133
Osteoarthritis Cartilage. 2021 Feb;29(2):180-189
pubmed: 33242603
Stroke. 2009 Oct;40(10):3356-61
pubmed: 19661476
Vet J. 2017 Jan;219:12-14
pubmed: 28093103
Ann Rheum Dis. 2020 Jun;79(6):819-828
pubmed: 32398285
Arthritis Rheumatol. 2014 Sep;66(9):2461-71
pubmed: 24838404
Vet Comp Orthop Traumatol. 2014;27(3):210-5
pubmed: 24664192
Res Vet Sci. 2014 Jun;96(3):429-35
pubmed: 24684895
J Neurochem. 2016 Jul;138(2):328-38
pubmed: 27060873
Vet Surg. 2005 Sep-Oct;34(5):482-90
pubmed: 16266341
J Neurol Sci. 2017 Aug 15;379:29-35
pubmed: 28716263
BMC Musculoskelet Disord. 2012 Jul 23;13:126
pubmed: 22824140
J Toxicol Environ Health A. 2004 Mar 26;67(6):513-24
pubmed: 14742096
Med Pharm Rep. 2020 Jan;93(1):12-22
pubmed: 32133442
J Vet Sci. 2011 Sep;12(3):273-80
pubmed: 21897101
Eur J Pharmacol. 2019 Jun 5;852:14-24
pubmed: 30796902
J Neurochem. 2014 Apr;129(2):339-49
pubmed: 24286176
J Neurochem. 2008 Feb;104(3):708-18
pubmed: 17995940
Mol Pharmacol. 2006 Mar;69(3):1056-65
pubmed: 16368895
Osteoarthritis Cartilage. 2015 Aug;23(8):1233-41
pubmed: 25865392
Vet Clin North Am Small Anim Pract. 2008 Nov;38(6):1449-70, viii
pubmed: 18954692
J Alzheimers Dis. 2018;61(2):571-580
pubmed: 29226874
Toxicol Sci. 2015 Feb;143(2):242-55
pubmed: 25628402
Sci Rep. 2017 Apr 12;7:45741
pubmed: 28401906
Neuroscience. 2011 Jan 26;173:150-5
pubmed: 21081153
Vet Rec. 2017 Apr 1;180(13):328-329
pubmed: 28364073
Arthritis Rheum. 2006 Jan;54(1):271-81
pubmed: 16385544
Arthritis Rheum. 2005 Sep;52(9):2799-807
pubmed: 16145669
Cardiovasc Res. 2010 Feb 1;85(3):413-23
pubmed: 19656780
Arthritis Rheum. 2004 Jul;50(7):2151-6
pubmed: 15248212
J Neurochem. 2017 Jun;141(5):708-720
pubmed: 28301040
J Neurochem. 2011 May;117(3):554-64
pubmed: 21352229
J Biol Chem. 1998 Jun 26;273(26):16058-66
pubmed: 9632657
Neurobiol Aging. 2006 Aug;27(8):1094-9
pubmed: 15993986
Eur J Pharmacol. 2008 Feb 2;580(1-2):48-54
pubmed: 18022616
J Knee Surg. 2011 Dec;24(4):251-64
pubmed: 22303754